Organogenesis Shares Jump After PuraPly AM Hits Primary Endpoint in DFU Trial
Organogenesis Holdings Inc. saw its stock climb 20% after announcing that PuraPly AM met the primary endpoint in a randomized controlled trial for non-healing diabetic foot ulcers. The prospective, multi-center trial of 170 patients found statistically significant wound closure at 12 weeks for patients treated with PuraPly AM plus standard of care …